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Abstract
Background: Tauopathies comprise a family of neurodegenerative disorders including Alzheimer’s disease for
which there is an urgent and unmet need for disease-modifying treatments. Tauopathies are characterized by
pathological tau hyperphosphorylation, which has been shown to correlate tightly with disease progression and
memory loss in patients suffering from Alzheimer’s disease. We recently demonstrated an essential requirement
for 3-O-sulfated heparan sulfate in pathological tau hyperphosphorylation in zebrafish, a prominent model organism
for human drug discovery. Here, we investigated whether in vivo treatment with surfen or its derivatives oxalyl surfen
and hemisurfen, small molecules with heparan sulfate antagonist properties, could mitigate tau hyperphosphorylation
and neuronal deficits in a zebrafish model of tauopathies.
Results: In vivo treatment of Tg[HuC::hTauP301L; DsRed] embryos for 2 days with surfen or oxalyl surfen significantly
reduced the accumulation of the pThr181 tau phospho-epitope measured by ELISA by 30% and 51%, respectively.
Western blot analysis also showed a significant decrease of pThr181 and pSer396/pSer404 in embryos treated with
surfen or oxalyl surfen. Immunohistochemical analysis further confirmed that treatment with surfen or oxalyl surfen
significantly decreased the AT8 tau epitope in spinal motoneurons. In addition, in vivo treatment of Tg[HuC::hTauP301L;
DsRed] embryos with surfen or oxalyl surfen significantly rescued spinal motoneuron axon-branching defects and, as a
likely consequence, the impaired stereotypical touch-evoked escape response. Importantly, treatment with hemisurfen,
a surfen derivative devoid of heparan sulfate antagonist activity, does not affect tau hyperphosphorylation, nor
neuronal or behavioural deficits in Tg[HuC::hTauP301L; DsRed] embryos.
Conclusion: Our findings demonstrate for the first time that surfen, a well-tolerated molecule in clinical settings, and
its derivative, oxalyl surfen, could mitigate or delay neuronal defects in tauopathies, including Alzheimer’s disease.
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Introduction
Tauopathies comprise more than 20 neurodegenerative dis-
eases including Alzheimer’s disease (AD), frontotemporal
dementia (FTD), Pick’s disease, progressive supranuclear
palsy (PSP) and other related disorders. Tauopaties are
characterized by accumulation of hyperphosphorylated iso-
forms of the microtubule-associated tau protein in brain
forming distinct inclusions [1].
We have recently shown that in vivo depletion of Hs3st2,
an enzyme involved in 3-O-sulfation of heparan sulfate
chains and predominantly expressed in neuronal cells, sig-
nificantly decreased tau hyperphosphorylation and partially
rescued neuronal and behaviour defects in transgenic
Tg[HuC::hTauP301L; DsRed] zebrafish embryos [2].
Tg[HuC::hTauP301L; DsRed] embryos display key features of
tauopathies, such as tau hyperphosphorylation [3]. These
findings suggest that inhibition of heparan sulfate-related
activities could have beneficial therapeutic effects for tauo-
pathies. Here, we have tested the hypothesis that treatment
of Tg[HuC::hTauP301L; DsRed] zebrafish embryos with small
molecules displaying heparan sulfate antagonist properties
could mitigate pathological tau hyperphosphorylation and
rescue the induced neuronal and behavioural deficits.
Glycosaminoglycan (GAG)-protein interactions have
long been recognized as therapeutic targets in various dis-
ease conditions such as cancer, inflammation and AD [4,
5]. Inhibition of harmful processes mediated by endogen-
ous GAGs, by treatment with exogenous GAGs or GAG
mimetics, has been developed as a therapeutic strategy in
Alzheimer’s disease [6–8]. Surfen (1,3-bis (4-amino-2-
methylquinolin-6-yl) urea) is a quinolone-based low MW
derivative, which was initially developed for the produc-
tion of depot insulin for diabetic patients [9]. This well-
tolerated substance was later shown to possess antibacter-
ial, trypanocidal, and anti-inflammatory properties [10–
12]. Of particular interest, surfen was later shown to ex-
hibit heparin-neutralizing activity and the ability to
antagonize heparan sulfate (HS)-protein interactions [5,
13]. As a first attempt to investigate the effects of surfen
and its analogs, on tau hyperphosphorylation, we have
examined whether surfen and two recently synthesized
surfen derivatives, oxalyl surfen (N1,N2-bis(4-amino-2-
methylquinolin-6-yl)oxalamide) and hemisurfen (1-(4-
amino-2-methylquinolin-6-yl)urea) [14], could reduce tau
hyperphosphorylation and alleviate neuron defects in vivo
in Tg[HuC::hTauP301L; DsRed] zebrafish embryos.
Results
Surfen, oxalyl surfen and hemisurfen are well tolerated in
zebrafish embryos
Initially, experiments were set up to analyze potential
toxicity of the surfen analogs used in this study, (Fig. 1a).
One set of 24 h post-fertilization (hpf ) zebrafish
Tg[HuC::hTauP301L, DsRed] embryos were incubated for
2 days in E3 medium containing 1% DMSO and surfen,
oxalyl surfen or hemisurfen. As negative controls, age-
matched wild-type and Tg[HuC::hTauP301L, DsRed] em-
bryos were incubated for 2 days in E3 medium contain-
ing 1% DMSO. As positive control, age-matched
Tg[HuC::hTauP301L, DsRed] embryos were incubated in
E3 medium containing 1% DMSO and 1 lithium chloride
(LiCl), a long known inhibitor of tau hyperphosphoryla-
tion [15]. For each agent, operational concentrations
were defined as the highest concentration not inducing
any visible morphological abnormalities, including heart
rhythm and blood flow defects (Fig. 1b), nor any signifi-
cant increase in embryo lethality (Additional file 1: Fig-
ure S1c). Operational concentrations (3 μM for surfen,
2 μM for oxalyl surfen, and 3 μM for hemisurfen) were
then used for all subsequent experiments.
Surfen and oxalyl surfen reduce tau
hyperphosphorylation in vivo
As a first attempt to determine whether treatment with
surfen, oxalyl surfen or hemisurfen could decrease tau
hyperphosphorylation in vivo, we quantified tau pThr181
phosphorylation by ELISA assay. Treatment of 24 hpf
Tg[HuC::hTauP301L; DsRed] embryos for 2 days with sur-
fen or oxalyl surfen, decreased the accumulation of hyper-
phosphorylated tau by 30% and 51%, respectively (surfen
and oxalyl surfen: P < 0.05), when compared to embryos
treated with 1% DMSO (Fig. 2a). In contrast, no signifi-
cant differences in pThr181 phospho-tau accumulation
could be detected in embryos incubated with hemisurfen
(P = 0.83, Fig. 2a). As expected, treatment with LiCl re-
sulted in a 43% decrease in hyperphosphorylated tau when
compared to embryos treated with 1% DMSO (N = 5, n =
250 (number of embryos); P < 0.05, Fig. 2a).
To confirm the ELISA results, we performed Western
blot analysis with antibodies directed against either the
pThr181 (AT270) or pSer396/pSer404 (PHF1) phospho-
tau epitopes (Fig. 2b). Data showed a significant decrease
in accumulation of both epitopes following treatment
with surfen, oxalyl surfen and LiCl (P < 0.05). In con-
trast, hemisurfen did not significantly affect tau phos-
phorylation on AT270 nor PHF1 epitopes, (P = 0.42) and
(P = 0.12) respectively (Fig. 2b, c, d).
To further investigate the effects of surfen and its deriv-
atives on tau hyperphosphorylation, Tg[HuC::hTauP301L;
DsRed] embryos were analysed by immunohistochemistry
using the AT8 antibody directed against the pSer202/
pThr205 phospho-tau epitope and the anti-total-tau K9JA
antibody (Fig. 2e). In good agreement with both the ELISA
results and Western blot analysis, a significant decrease in
AT8/Total tau labelling intensity ratio was observed in the
spinal cord of Tg[HuC::hTauP301L; DsRed] embryos treated
with surfen, oxalyl surfen and LiCl (P < 0.05), but not
hemisurfen (P = 0.3) (Fig. 2f). Interestingly, surfen or
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oxalyl surfen, decreases the somato-dendritic localization
of hTauP301L (Fig. 2e), a feature of tau pathology in AD
and FTD [16]. As tau missorting is linked to tau hyper-
phosphorylation, the decrease in somato-dendritic tau
might be a consequence of the decrease in tau phosphor-
ylation. In general, we observed stronger effects of oxalyl
surfen than surfen (Fig. 2).
Surfen and oxalyl surfen rescue motoneuron defects and
behavioral deficits
Tg[HuC::hTauP301L; DsRed] larvae displayed markedly
reduced motoneuron axon-branching and elongation,
and, as a likely consequence, they showed an impaired
escape response to touch stimuli [3]. Because surfen and
oxalyl surfen markedly decrease tau hyperphosphoryla-
tion, we next investigated whether treatment with these
two compounds could rescue, at least partially, neuronal
deficits and promote functional recovery. First, we ana-
lysed motoneuron axon morphology by immunohisto-
chemistry using znp1 [17], an antibody that specifically
recognizes synaptotagmin II, a synaptic protein highly
expressed in primary motoneuron axons. Results showed
that treatment with surfen, oxalyl surfen, and LiCl, but
not hemisurfen, significantly increased primary moto-
neuron branching in Tg[HuC::hTauP301L, DsRed] em-
bryos (1% DMSO vs. surfen-treated embryos: P < 0.001;
1% DMSO vs. oxalyl surfen-treated embryos: P < 0.05;
1% DMSO vs. LiCl-treated embryos: P < 0.01; 1% DMSO
Fig. 1 Surfen and oxalyl surfen are well tolerated by Tg[HuC::hTauP301L; DsRed] embryos. a Chemical structure of Surfen (1,3-bis(4-amino-2-
methylquinolin-6-yl) urea), oxalyl surfen (N1,N2- bis(4-amino-2-methylquinolin-6-yl)oxalamide) and hemisurfen (1-(4-amino-2-methylquinolin-6- yl)urea).
b Phenotypic analysis of 72 hpf wild-type (WT) and Tg[HuC::hTauP301L; DsRed] (hTauP301L) embryos incubated for 2 days in E3 medium containing 1%
DMSO (hTauP301L + 1% DMSO), 80 mM LiCl (hTauP301L + LiCl), 3 μM surfen (hTauP301L + surfen), 2 μM oxalyl surfen (hTauP301L + oxalyl surfen) or 3 μM
hemisurfen (hTauP301L + hemisurfen), showed that embryonic development is not impaired by the treatments. Magnification × 40. c Survival rate of 72
hpf wild-type (WT) and Tg[HuC::hTauP301L; DsRed] (hTauP301L) embryos incubated for 2 days in E3 medium containing 1% DMSO (hTauP301L + 1%
DMSO), 80 mM LiCl (hTauP301L + LiCl), 3 μM surfen (hTauP301L + surfen), 2 μM oxalyl surfen (hTauP301L + oxalyl surfen), or 3 μM hemisurfen (hTauP301L +
hemisurfen), demonstrated that embryonic mortality was not significantly increased by treatments (n = 250, P > 0.05, Student’s t test)
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Fig. 2 (See legend on next page.)
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vs. hemisurfen-treated embryos: P = 0.43) (Fig. 3a and
b).
Next, we quantified znp1 staining in wild-type and in
treated and 1% DMSO Tg[HuC::hTauP301L; DsRed] em-
bryos. As previously shown [3], a significant decrease in
znp1 staining was observed in 1% DMSO Tg[HuC::h-
TauP301L, DsRed] individuals when compared to age-
matched wild-type embryos (P < 0.05) (Fig. 3a and c). Inter-
estingly, znp1 staining in Tg[HuC::hTauP301L; DsRed] em-
bryos was significantly rescued following a 2 day treatment
with surfen (P < 0.01), oxalyl surfen (P < 0.05), and LiCl
(P < 0.01), but not hemisurfen (P = 0.21) (Fig. 3a and c).
We next assessed whether treatment with surfen or oxa-
lyl surfen could rescue the motility defects of Tg[HuC::h-
TauP301L; DsRed] zebrafish larvae in response to touch
stimuli. As previously shown, Tg[HuC::hTauP301L; DsRed]
zebrafish larvae showed significantly impaired motility
characterized by slower movements and reduced touch-
induced escape when compared to wild-type age-matched
larvae (wild-type vs. 1% DMSO Tg[HuC::hTauP301L;
DsRed] embryos: P < 0.05) (Fig. 3d). Interestingly, treat-
ment with surfen or oxalyl surfen, fully rescued the motil-
ity deficit (surfen and oxalyl surfen vs. 1% DMSO: P <
0.05; Fig. 3d), while treatment with hemisurfen had no ef-
fect on motility defects (P = 0.27; Fig. 3d). These results
provided functional evidence that surfen and oxalyl surfen
not only significantly decrease tau hyperphosphorylation,
but also alleviate the behavioural consequences of the
neuronal deficits induced by the expression of the human
mutant tauP301L protein.
Discussion
Here we showed that treatment with surfen, or its ana-
log, oxalyl surfen, significantly decreased tau hyperpho-
sphorylation and rescued motoneuron defects and
behavioral abnormalities induced by expression of mu-
tant hTauP301L in Tg[HuC::hTauP301L; DsRed] zebrafish.
In contrast, hemisurfen did not affect tau phosphoryl-
ation, motoneuron and behavioural deficits. Surfen has
been shown to inhibit heparan sulfate-protein interac-
tions [13], whereas hemisurfen does not [14]. Thus sur-
fen and oxalyl surfen may mediate their beneficial
effects by blocking heparan sulfate-tau interactions.
Taken together, these results strengthen the hypothesis
of a substrate modulator effect of highly sulfated HS
chains on tau, possibly through a chaperone-like activ-
ity uncovering the tau residues that are phosphorylated
in pathological situations. In this context, surfen and
oxalyl surfen may inhibit the chaperone activity of sul-
fated polysaccharide chains, thus preventing tau hyper-
phosphorylation. It is also possible that the decline in
tau phosphorylation mediated by surfen and oxalyl sur-
fen is due to alterations of heparan sulfate biosynthesis
or metabolism. Surfen may affect heparan sulfate struc-
ture and stability, as it has been previously shown in
vitro that surfen prevents interaction of heparin with
heparin biosynthetic and degrading enzymes (Schuksz
et al.). However, it should also be noted that surfen also
displays Ca channel blocker [18], zinc ion binding [11]
and immunomodulatory activities [10, 19]. These prop-
erties can potentially affect pathophysiological mecha-
nisms in tauopathies. Calcium deregulation is reported
to contribute to neurodegeneration in iPSC-derived
neurons from FTD patients [20]. Surfen may affect cal-
cium levels by blocking calcium channels or modulat-
ing calcium channels through interaction with heparan
sulfate [21]. Zinc ion (Zn2+) has been implicated in tau
fibrillization and toxicity [22, 23]. A c5a receptor antag-
onist is reported to decrease tau hyperphosphorylation
in 3xTg mouse model of Alzheimer’s disease [24], while
(See figure on previous page.)
Fig. 2 Treatments with surfen and oxalyl surfen, but not hemisurfen, decrease tau hyperphosphorylation in Tg[HuC::hTauP301L; DsRed] embryos
in vivo. a ELISA quantification of pThr181 in 72 hpf Tg[HuC::hTauP301L; DsRed] (hTauP301L) embryos treated for 2 days in E3 medium containing
1% DMSO (hTauP301L + 1% DMSO), 80 mM LiCl (hTauP301L + LiCl), 3 μM surfen, (hTauP301L + surfen), 2 μM oxalyl surfen (hTauP301L + oxalyl
surfen), or 3 μM hemisurfen (hTauP301L + hemisurfen). The values were normalized to total human Tau protein recovered in each sample.
pThr181 was significantly decreased in Tg[HuC::hTauP301L; DsRed] embryos treated with LiCl, surfen and oxalyl surfen, but not hemisurfen (* P
< 0.05, ns: not significant, Student’s t test). b Western blot analysis of pThr181 (AT270 antibody), pSer396/pSer404 (PHF1 antibody) and total-
Tau (K9JA antibody) in 1% DMSO 72 hpf Tg[HuC::hTauP301L; DsRed] (hTauP301L) embryos and in age-matched siblings treated for 2 days with
80 mM LiCl, 3 μM surfen, 2 μM oxalyl surfen or 3 μM hemisurfen, confirmed that treatments with surfen or oxalyl surfen, but not hemisurfen,
markedly reduce tau hyperphosphorylation in Tg[HuC::hTauP301L; DsRed] embryos. c Densitometric analysis of AT270 on Western blots
(represented in b) showing significant decrease of AT270/K9JA densitometric intensity ratio with LiCl, surfen and oxalyl surfen treatment, but
not hemisurfen (n = 3, * P < 0.05, ns: non-significant, Student’s t test). d Densitometric analysis of PHF1 staining intensity on Western blots
(represented in b) showing significant decrease of PHF1/K9JA densitometric intensity ratio with LiCl, surfen and oxalyl surfen treatment, but
not hemisurfen (n = 3, * P < 0.05, ns: non-significant, Student’s t test). e Immunohistochemical visualization of total hTau protein (K9JA) and
hyperphosphorylated tau epitope pSer202/pThr205 (AT8), and merged images of the two labelings (merge) in framed caudal area (f) in spinal
cord of 72 hpf Tg[HuC::hTauP301L; DsRed] embryos and age-matched siblings incubated for 2 days with 80 mM LiCl (hTauP301L + LiCl), 3 μM
surfen (hTauP301L + surfen), 2 μM oxalyl surfen (hTauP301L + oxalyl surfen) or 3 μM hemisurfen (hTauP301L + hemisurfen), confirmed the decrease
of tau hyperphosphorylation following treatments with surfen and oxalyl surfen. g Quantification of AT8 fluorescence intensity. The AT8/K9JA
fluorescence intensity ratio was significantly decreased following treatments with LiCl, surfen and oxalyl surfen, but not hemisurfen (n = 10, *
P < 0.05, ns: non-significant, Student’s t test). Scale bar: 50 μm
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Fig. 3 Surfen and oxalyl surfen rescue motoneuron defects and functional deficits in Tg[HuC::hTauP301L; DsRed] embryos. a Immunohistochemical
visualization of the synaptotagmin II protein (anti-znpl antibody) in 72 hpf wild-type (WT) and Tg[HuC::hTauP301L; DsRed] (hTauP301L) embryos
treated for 2 days with 1% DMSO (hTauP301L + 1% DMSO), 80 mM LiCl (hTauP301L + LiCl), 3 μM surfen (hTauP301L + surfen), 2 μM oxalyl surfen
(hTauP301L + oxalyl surfen) or 3 μM hemisurfen (hTauP301L + hemisurfen), showed that surfen and oxalyl surfen markedly rescued the motorneuron
axon defects seen in Tg[HuC::hTauP301L; DsRed] embryos. The imaged caudal area corresponds to the box represented in (b). Scale bar: 50 μm. c
Quantification of the mean axonal branch number in the framed caudal area (b) of Tg[HuC::hTauP301L; DsRed] embryos treated as in (a). The
number of axonal branches was significantly increased in Tg[HuC::hTauP301L; DsRed] embryos treated with surfen and oxalyl surfen when com-
pared with their age-matched 1% DMSO siblings (n = 10, ***P < 0.001; **P < 0.01; *P < 0.05; ns: non-significant, Student’s t test). d Quantification of
fluorescence staining intensity of znp1 labeling in the framed caudal area (b) of Tg[HuC::hTauP301L; DsRed] embryos treated as in (a). Results
showed that the fluorescence intensity of the znp1 staining was significantly increased in Tg[HuC::hTauP301L; DsRed] embryos following surfen
and oxalyl surfen treatments when compared with their age-matched 1% DMSO siblings (n = 10, **P < 0.01; *P < 0.05, ns: non-significant, Student’s
t test). e The touch evoked escape response was used to probe the motor behavior of Tg[HuC::hTauP301L; DsRed] embryos treated for 1 day with
80 mM LiCl, 3 μM surfen, 2 μM oxalyl surfen or 3 μM hemisurfen. The motor defect observed in Tg[HuC::hTauP301L; DsRed] embryos was
significantly rescued following treatment with surfen and oxalyl surfen, but not hemisurfen (n = 250, *P < 0.05, ns: non-significant, Student’s t test)
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surfen also acts as an inhibitor of c5a receptor binding
[10].
Importantly, apart from rare reports of hypersensitivity
reactions [25, 26], surfen is well tolerated in clinical set-
tings. Although one study linked high doses and pro-
longed administration of surfen to lymphosarcoma and
lesions reminiscent of nutritional deficiency, surfen is
well tolerated in mice [13]. In good agreement, we found
surfen and oxalyl surfen to be well tolerated in zebrafish
embryos at the effective concentrations of 3 μM and
2 μM, respectively. Oxalyl surfen shows a stronger effect
on tau phosphorylation and behavioural rescue than sur-
fen, suggesting the molecule to be more efficient against
tau pathology. However, the derivative is toxic to zebra-
fish embryos at a lower concentration, pointing out a
potentially less favourable safety profile than surfen. Fur-
ther investigations are needed to determine whether the
two molecules could also counteract neurodegenerative
processes linked to tau alterations in humans.
Materials and methods
Animals
Zebrafish were maintained at 28 °C in our zebrafish fa-
cility under standard conditions as described by Wester-
field (1995) [27]. Developmental stages were determined
as hours post-fertilization (hpf ) as described by Kimmel
et al. [28]. AB strain was used as wild-type fish. The zeb-
rafish transgenic line stably expressing the human mu-
tant TauP301L protein that is associated with
frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) (the Tg[HuC::hTauP301L;
DsRed]), has been previously described [3], and was
kindly provided by Christian Haass, Bettina Schmid, and
Dominik Paquet (Deutsches Zentrum für Neurodegener-
ative Erkrankungen or DZNE, Munich, Germany).
Compounds
Surfen (1,3-bis(4-amino-2-methylquinolin-6-yl)urea) was
obtained from the Open Chemical Repository in the De-
velopmental Therapeutic Program at the National Cancer
Institute (NSC12155) or synthesized according to
published methods. The synthesis and characterization of
oxalyl surfen (N1,N2-bis(4-amino-2-methylquinolin-6-
yl)oxalamide) and hemisurfen (1-(4-amino-2-methylqui-
nolin-6-yl)urea) have been previously described [14, 29].
Treatments
As surfen and oxalyl surfen bind avidly to plastic, we ei-
ther pre-coated all plasticware with serum containing
medium or used glass vessels. Stock solutions (surfen
and hemisurfen, 30 mM; oxalyl surfen, 21.7 mM) were
prepared in DMSO. Working solutions were prepared as
needed by diluting stock solutions in E3 medium and
adjusting the DMSO concentration to 1% (vol/vol). Final
concentrations for treatments were determined as 3 μM
for surfen, 2 μM for oxalyl surfen, 3 μM for hemisurfen
and 80 mM for lithium chloride (LiCl) based on max-
imal non-toxic concentrations for zebrafish embryos
(Additional file 1). Embryos (24 hpf ) were manually
dechorionated and incubated for 2 days in 1–2 ml of ei-
ther control medium (E3 medium containing 1%
DMSO) or E3 medium containing 1% DMSO and the
surfen derivatives in BSA-coated 6-well microtiter plates.
All solutions were changed daily.
ELISA
Embryos treated as previously described were anaesthe-
tized with MS-222 in E3 medium on ice. After removal
of the yolk, embryos were snap frozen on dry ice and
homogenized by sonication in lysis buffer (50 mM Tris
HCl, 150 mM NaCl, 10% Triton X100, 1 mM EDTA, 1X
Protease Inhibitor Cocktail [Roche], 1 mM Sodium
orthovanadate (NaVO4) [Sigma-Aldrich], and 1 mM So-
dium fluoride (NaF), pH 8). Insoluble material was re-
moved by a 30 min centrifugation (10,000 g) at 4 °C and
protein concentration was determined with Bradford
protein assay (Bio-Rad). Accumulation of phosphory-
lated tau was quantified using the INNOTEST®
Phospho-Tau (181P) ELISA (Innogenetics, Gent
Belgium), using mAb HT7 for coating, phospho-
dependent mAb AT270 (specific for phospho-threonine-
181 tau epitope) as detector antibody, and a synthetic
phosphopeptide for standardization.
Western blot
Zebrafish larvae were collected, anaesthetized in MS-
222, and lysed on ice with lysis buffer (50 mM Tris-HCl,
150 mM NaCl, 1% Triton X-100, 10 mM NaF, 1 mM
Na3VO4, pH 8.0) supplemented with protease and phos-
phatase inhibitors (Pierce). Lysates were homogenized
by sonication and centrifuged at 12000 g for 15 min.
The protein content in the supernatants was quantified
using a Bradford protein assay (Bio-Rad).
Samples containing 10 μg proteins were subjected to
SDS-PAGE in 10% acrylamide gel. Primary antibodies
against phosphorylated tau, AT270 and PHF1 (Pierce,
Thermo Scientific), anti-human total tau antibody K9JA
(Rabbit Polyclonal Antibody, Dako Cytomation), and
anti-GADPH (Abcam) were used. Blots were subse-
quently incubated for 1 h at room temperature with the
corresponding secondary antibodies diluted in
phosphate-buffered saline containing 5% milk and re-
vealed using ECL RevelBlOt® Plus (Ozyme) following
manufacturer’s instructions.
Immunohistochemistry
For immunohistochemical analysis, embryo pigmenta-
tion was inhibited by treatment with 0.2 mM 1-phenyl-
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2-thiourea (PTU) in E3 medium starting at 20 hpf. After
anaesthesia with MS-222, whole embryos were fixed in 4%
paraformaldehyde in PBS, and preserved in methanol
(MeOH) 100%. Fixed and acetone-cracked embryos were
then blocked and permeabilized for 1 h at room
temperature in a PBS solution containing 10% NGS, 1%
DMSO and 0.1% Tween 20. Embryos were then incubated
overnight at room temperature with the phosphorylation-
independent primary anti-human total tau antibody K9JA
(Rabbit Polyclonal Antibody, Dako Cytomation) diluted at
1:300, the phosphorylation-dependent site specific anti-
PHF-Tau antibody AT8 diluted at 1:50 (gift from D.
Paquet), and anti-Znp-1 (Mouse Monoclonal Antibody;
Hybridoma Bank, Iowa, USA) (1:300) to investigate the
morphology of primary motoneurons. After several
washes, embryos were blocked as previously described
[30], and incubated overnight at 4 °C with a solution con-
taining CY3-coupled goat anti-rabbit (1:500) and Alexa
Fluor 488-coupled goat anti-mouse antibody (1:500). Em-
bryos were mounted in 1% agarose (low melting, Bio-Rad)
in PBS buffer.
Image analysis
Bright field images of embryos were captured using a
stereomicroscope (SteREO Lumar. V12, Zeiss) equipped
with a digital camera (DXM 1200F, Nikon) controlled by
the ACT-1 software (Version 2.63 Nikon). Fluorescently
labelled embryos were imaged using a microscope
equipped with an ApoTome system (Zeiss) fitted with an
AxioCam MRm camera (Zeiss) controlled by the Axiovi-
sion or ZEN software. All images were processed with
Adobe Photoshop 7.0 (Adobe System, San Jose, CA).
When necessary, brightness, contrast, and colour balance,
were uniformly optimized. Fluorescence intensities and
densimetric quantification of protein immunoblots were
performed using ImageJ/Fiji (Rasband, W.S., ImageJ, U. S.
National Institutes of Health, Bethesda, Maryland, USA,
http://imagej.nih.gov/ij/, 1997–2012) on grayscale images.
For each value, quantifications were performed using im-
ages from three independent experiments.
Behavioural analysis
Larvae behaviour was analysed at 48 hpf after 1 day
treatments with the different compounds. The larval es-
cape response reflex was assessed by gently touching the
tip of the tail with a fine plastic rod. Embryos were clas-
sified as responders or non-responders, with non-
responders failing to respond by swimming at least three
times their own body length.
Statistics
Values for mean, standard deviation (SD) and standard
error of mean (SEM) were calculated using Microsoft
Excel, version 12.0.6683.5002. Statistical analysis was
performed using Microsoft Excel and Student’s t test.
Error bars represent SEM, *P < 0.05, ** P < 0.01, ***P
< 0.001.
Additional file
Additional file 1: Figure S1. Percentage of embryonic survival
observed for 72 hpf wild-type (WT) and Tg[HuC::hTauP301L; DsRed] (non-
treated) embryos incubated for 2 days in E3 medium containing 1%
DMSO or E3 medium containing 1% DMSO with LiCl (10–150 mM) (a),
surfen (0.1–10 μM) (b), oxalyl surfen (0.1–10 μM) (c) or hemisurfen (0.1–
10 μM) (d). Note that at the selected concentrations (80 mM LiCl, 3 μM
for surfen and hemisurfen and 2 μM for oxalyl surfen) are the maximal
non-toxic concentrations (n = 250, *P < 0.05, ***P < 0.001, ns: non-
significant, Student’s t test). (TIFF 55462 kb)
Abbreviations
AD: Alzheimer’s disease; DMSO: Dimethyl sulfoxide; dpf: Days post
fertilization; FTD: Frontotemporal dementia; hpf: Hours post fertilization;
LiCl: Lithium chloride
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